Adverse Drug Reactions to Guideline-Recommended Heart Failure Drugs in Women

A Systematic Review of the Literature

Sophie H. Bots, Floor Groepenhoff, Anouk L.M. Eikendal, Cara Tannenbaum, Paula A. Rochon, Vera Regitz-Zagrosek, Virginia M Miller, Danielle Day, Folkert W. Asselbergs, Hester M. den Ruijter

Research output: Contribution to journalArticle

Abstract

Objectives: This study sought to summarize all available evidence on sex differences in adverse drug reactions (ADRs) to heart failure (HF) medication. Background: Women are more likely to experience ADRs than men, and these reactions may negatively affect women's immediate and long-term health. HF in particular is associated with increased ADR risk because of the high number of comorbidities and older age. However, little is known about ADRs in women with HF who are treated with guideline-recommended drugs. Methods: A systematic search of PubMed and EMBASE was performed to collect all available information on ADRs to angiotensin-converting enzyme inhibitors, β-blockers, angiotensin II receptor blockers, mineralocorticoid receptor antagonists, ivabradine, and digoxin in both women and men with HF. Results: The search identified 155 eligible records, of which only 11 (7%) reported ADR data for women and men separately. Sex-stratified reporting of ADRs did not increase over the last decades. Six of the 11 studies did not report sex differences. Three studies reported a higher risk of angiotensin-converting enzyme inhibitor–related ADRs in women, 1 study showed higher digoxin-related mortality risk for women, and 1 study reported a higher risk of mineralocorticoid receptor antagonist–related ADRs in men. No sex differences in ADRs were reported for angiotensin II receptor blockers and β-blockers. Sex-stratified data were not available for ivabradine. Conclusions: These results underline the scarcity of ADR data stratified by sex. The study investigators call for a change in standard scientific practice toward reporting of ADR data for women and men separately.

Original languageEnglish (US)
Pages (from-to)258-266
Number of pages9
JournalJACC: Heart Failure
Volume7
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

Drug-Related Side Effects and Adverse Reactions
Heart Failure
Guidelines
Pharmaceutical Preparations
ivabradine
Sex Characteristics
Angiotensin Receptor Antagonists
Digoxin
Mineralocorticoid Receptor Antagonists
Mineralocorticoid Receptors
Peptidyl-Dipeptidase A
Angiotensin-Converting Enzyme Inhibitors
PubMed
Comorbidity
Research Personnel

Keywords

  • adverse drug reactions
  • heart failure
  • sex differences
  • sex-specific reporting
  • women

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Bots, S. H., Groepenhoff, F., Eikendal, A. L. M., Tannenbaum, C., Rochon, P. A., Regitz-Zagrosek, V., ... den Ruijter, H. M. (2019). Adverse Drug Reactions to Guideline-Recommended Heart Failure Drugs in Women: A Systematic Review of the Literature. JACC: Heart Failure, 7(3), 258-266. https://doi.org/10.1016/j.jchf.2019.01.009

Adverse Drug Reactions to Guideline-Recommended Heart Failure Drugs in Women : A Systematic Review of the Literature. / Bots, Sophie H.; Groepenhoff, Floor; Eikendal, Anouk L.M.; Tannenbaum, Cara; Rochon, Paula A.; Regitz-Zagrosek, Vera; Miller, Virginia M; Day, Danielle; Asselbergs, Folkert W.; den Ruijter, Hester M.

In: JACC: Heart Failure, Vol. 7, No. 3, 01.03.2019, p. 258-266.

Research output: Contribution to journalArticle

Bots, SH, Groepenhoff, F, Eikendal, ALM, Tannenbaum, C, Rochon, PA, Regitz-Zagrosek, V, Miller, VM, Day, D, Asselbergs, FW & den Ruijter, HM 2019, 'Adverse Drug Reactions to Guideline-Recommended Heart Failure Drugs in Women: A Systematic Review of the Literature', JACC: Heart Failure, vol. 7, no. 3, pp. 258-266. https://doi.org/10.1016/j.jchf.2019.01.009
Bots, Sophie H. ; Groepenhoff, Floor ; Eikendal, Anouk L.M. ; Tannenbaum, Cara ; Rochon, Paula A. ; Regitz-Zagrosek, Vera ; Miller, Virginia M ; Day, Danielle ; Asselbergs, Folkert W. ; den Ruijter, Hester M. / Adverse Drug Reactions to Guideline-Recommended Heart Failure Drugs in Women : A Systematic Review of the Literature. In: JACC: Heart Failure. 2019 ; Vol. 7, No. 3. pp. 258-266.
@article{a3739efbcd4b49bd8615fdd1d33d5eb0,
title = "Adverse Drug Reactions to Guideline-Recommended Heart Failure Drugs in Women: A Systematic Review of the Literature",
abstract = "Objectives: This study sought to summarize all available evidence on sex differences in adverse drug reactions (ADRs) to heart failure (HF) medication. Background: Women are more likely to experience ADRs than men, and these reactions may negatively affect women's immediate and long-term health. HF in particular is associated with increased ADR risk because of the high number of comorbidities and older age. However, little is known about ADRs in women with HF who are treated with guideline-recommended drugs. Methods: A systematic search of PubMed and EMBASE was performed to collect all available information on ADRs to angiotensin-converting enzyme inhibitors, β-blockers, angiotensin II receptor blockers, mineralocorticoid receptor antagonists, ivabradine, and digoxin in both women and men with HF. Results: The search identified 155 eligible records, of which only 11 (7{\%}) reported ADR data for women and men separately. Sex-stratified reporting of ADRs did not increase over the last decades. Six of the 11 studies did not report sex differences. Three studies reported a higher risk of angiotensin-converting enzyme inhibitor–related ADRs in women, 1 study showed higher digoxin-related mortality risk for women, and 1 study reported a higher risk of mineralocorticoid receptor antagonist–related ADRs in men. No sex differences in ADRs were reported for angiotensin II receptor blockers and β-blockers. Sex-stratified data were not available for ivabradine. Conclusions: These results underline the scarcity of ADR data stratified by sex. The study investigators call for a change in standard scientific practice toward reporting of ADR data for women and men separately.",
keywords = "adverse drug reactions, heart failure, sex differences, sex-specific reporting, women",
author = "Bots, {Sophie H.} and Floor Groepenhoff and Eikendal, {Anouk L.M.} and Cara Tannenbaum and Rochon, {Paula A.} and Vera Regitz-Zagrosek and Miller, {Virginia M} and Danielle Day and Asselbergs, {Folkert W.} and {den Ruijter}, {Hester M.}",
year = "2019",
month = "3",
day = "1",
doi = "10.1016/j.jchf.2019.01.009",
language = "English (US)",
volume = "7",
pages = "258--266",
journal = "JACC: Heart Failure",
issn = "2213-1779",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Adverse Drug Reactions to Guideline-Recommended Heart Failure Drugs in Women

T2 - A Systematic Review of the Literature

AU - Bots, Sophie H.

AU - Groepenhoff, Floor

AU - Eikendal, Anouk L.M.

AU - Tannenbaum, Cara

AU - Rochon, Paula A.

AU - Regitz-Zagrosek, Vera

AU - Miller, Virginia M

AU - Day, Danielle

AU - Asselbergs, Folkert W.

AU - den Ruijter, Hester M.

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Objectives: This study sought to summarize all available evidence on sex differences in adverse drug reactions (ADRs) to heart failure (HF) medication. Background: Women are more likely to experience ADRs than men, and these reactions may negatively affect women's immediate and long-term health. HF in particular is associated with increased ADR risk because of the high number of comorbidities and older age. However, little is known about ADRs in women with HF who are treated with guideline-recommended drugs. Methods: A systematic search of PubMed and EMBASE was performed to collect all available information on ADRs to angiotensin-converting enzyme inhibitors, β-blockers, angiotensin II receptor blockers, mineralocorticoid receptor antagonists, ivabradine, and digoxin in both women and men with HF. Results: The search identified 155 eligible records, of which only 11 (7%) reported ADR data for women and men separately. Sex-stratified reporting of ADRs did not increase over the last decades. Six of the 11 studies did not report sex differences. Three studies reported a higher risk of angiotensin-converting enzyme inhibitor–related ADRs in women, 1 study showed higher digoxin-related mortality risk for women, and 1 study reported a higher risk of mineralocorticoid receptor antagonist–related ADRs in men. No sex differences in ADRs were reported for angiotensin II receptor blockers and β-blockers. Sex-stratified data were not available for ivabradine. Conclusions: These results underline the scarcity of ADR data stratified by sex. The study investigators call for a change in standard scientific practice toward reporting of ADR data for women and men separately.

AB - Objectives: This study sought to summarize all available evidence on sex differences in adverse drug reactions (ADRs) to heart failure (HF) medication. Background: Women are more likely to experience ADRs than men, and these reactions may negatively affect women's immediate and long-term health. HF in particular is associated with increased ADR risk because of the high number of comorbidities and older age. However, little is known about ADRs in women with HF who are treated with guideline-recommended drugs. Methods: A systematic search of PubMed and EMBASE was performed to collect all available information on ADRs to angiotensin-converting enzyme inhibitors, β-blockers, angiotensin II receptor blockers, mineralocorticoid receptor antagonists, ivabradine, and digoxin in both women and men with HF. Results: The search identified 155 eligible records, of which only 11 (7%) reported ADR data for women and men separately. Sex-stratified reporting of ADRs did not increase over the last decades. Six of the 11 studies did not report sex differences. Three studies reported a higher risk of angiotensin-converting enzyme inhibitor–related ADRs in women, 1 study showed higher digoxin-related mortality risk for women, and 1 study reported a higher risk of mineralocorticoid receptor antagonist–related ADRs in men. No sex differences in ADRs were reported for angiotensin II receptor blockers and β-blockers. Sex-stratified data were not available for ivabradine. Conclusions: These results underline the scarcity of ADR data stratified by sex. The study investigators call for a change in standard scientific practice toward reporting of ADR data for women and men separately.

KW - adverse drug reactions

KW - heart failure

KW - sex differences

KW - sex-specific reporting

KW - women

UR - http://www.scopus.com/inward/record.url?scp=85061615004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061615004&partnerID=8YFLogxK

U2 - 10.1016/j.jchf.2019.01.009

DO - 10.1016/j.jchf.2019.01.009

M3 - Article

VL - 7

SP - 258

EP - 266

JO - JACC: Heart Failure

JF - JACC: Heart Failure

SN - 2213-1779

IS - 3

ER -